Minerva Neurosciences | NERV - Selling And Administration Expenses


Minerva Neurosciences reported $2.48M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Adma Biologics USD 20.19M 2.86M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
AstraZeneca USD 5.06B 455M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
CSL USD 1.23B 498M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
Takeda JPY 282.78B 29.23B Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024